Pancreatic Cancer Research

ResearcherUniversity of HelsinkiActive in the last 2 years

Pauli Antero Puolakkainen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2489-4371; OpenAlex author ID A5034799855. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: none · 2024: 3 papers · 2025: 5 papers

Papers 19

  1. Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Co-author DOI 10.1007/s00262-025-04072-6↗
  2. Therapeutic Eradication of Cancer-associated Fibroblasts Inhibits in vivo progression of Pancreatic Cancer Co-author DOI 10.1101/2025.11.04.686484↗
  3. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  4. Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts. Co-author DOI 10.1186/s13099-025-00698-0↗
  5. Correction: Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts. Co-author DOI 10.1186/s13099-025-00710-7↗
  6. A Calculator Approach to Select Neoadjuvant Therapy in Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2024.2486↗
  7. Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study. Co-author DOI 10.1002/cam4.70014↗
  8. Circulating necroptosis markers in chronic pancreatitis and pancreatic cancer: Associations with diagnosis and prognostic factors. Co-author DOI 10.1016/j.pan.2024.11.016↗
  9. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Co-author DOI 10.1016/j.ejso.2021.11.116↗
  10. Lipid Metabolic Reprogramming Extends beyond Histologic Tumor Demarcations in Operable Human Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0396↗
  11. Oncogenomic Changes in Pancreatic Cancer and Their Detection in Stool. Co-author DOI 10.3390/biom12050652↗
  12. Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Sy… Co-author DOI 10.3390/cancers14030525↗
  13. Pancreatic cancer is associated with aberrant monocyte function and successive differentiation into macrophages with inferior anti-tumour characteristics. Co-author DOI 10.1016/j.pan.2020.12.025↗
  14. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients. Co-author DOI 10.3390/ijms222312978↗
  15. Tumour-associated macrophages activate migration and STAT3 in pancreatic ductal adenocarcinoma cells in co-cultures. Co-author DOI 10.1016/j.pan.2017.04.013↗
  16. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0163064↗
  17. Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells. Last author DOI 10.7150/jca.12923↗
  18. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Co-author DOI 10.1007/s12032-014-0884-9↗
  19. Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancrea… Last author DOI 10.1089/jir.2012.0046↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanna E. Seppänen · 14 shared papers, 2013–2025 · strength 1.99
  2. Heidelinde Sammallahti · 4 shared papers, 2021–2025 · strength 0.76
  3. Virinder Kaur Sarhadi · 4 shared papers, 2021–2025 · strength 0.76
  4. Hamid Asadzadeh Aghdaei · 4 shared papers, 2021–2025 · strength 0.76
  5. Sakari Knuutila · 4 shared papers, 2021–2025 · strength 0.76
  6. Caj H. Haglund · 4 shared papers, 2016–2024 · strength 0.59
  7. Mehdi Azizmohammad Looha · 2 shared papers, 2025 · strength 0.46
  8. Amir Sadeghi · 2 shared papers, 2025 · strength 0.46
  9. Panu Aaltonen · 2 shared papers, 2022–2024 · strength 0.40
  10. Olli Carpén · 2 shared papers, 2022–2024 · strength 0.40
  11. Ville J. Sallinen · 1 shared paper, 2024 · strength 0.36
  12. Matilda Juusola · 2 shared papers, 2021–2022 · strength 0.31
  13. Rosa F. Hwang · 1 shared paper, 2025 · strength 0.25
  14. Matilda Roos-Mattila · 1 shared paper, 2025 · strength 0.25
  15. Riitta Lassila · 1 shared paper, 2024 · strength 0.23
  16. Johanna M. Louhimo · 1 shared paper, 2024 · strength 0.23
  17. Leena Kylänpää · 1 shared paper, 2024 · strength 0.23
  18. Hanna Belfrage · 1 shared paper, 2024 · strength 0.23
  19. Aino Salmiheimo · 3 shared papers, 2016–2017 · strength 0.21
  20. Santeri Artturi Pakola · 1 shared paper, 2025 · strength 0.20
  21. Akseli Hemminki · 1 shared paper, 2025 · strength 0.20
  22. Hanneke W. Wilmink · 1 shared paper, 2025 · strength 0.19
  23. Svein Olav Bratlie · 1 shared paper, 2025 · strength 0.19
  24. Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.19
  25. Peter Jo · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.